OGEN
Oragenics·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OGEN
Oragenics, Inc.
A company that develops antibiotics, oral health products and weight loss products
1990 Main Street, Suite 750, Sarasota, Florida 34236
--
Oragenics, Inc. (formerly Oragen Co., Ltd.) was established in November 1996, but its business activities did not start until 1999. The company is a developing company dedicated to the research and development of nasal drug delivery in the field of neurology and the fight against infectious diseases. The company's leading product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and can cross the blood-brain barrier, rapidly reducing swelling, oxidative stress and inflammation, while restoring proper blood flow through gene amplification.
Company Financials
EPS
OGEN has released its 2025 Q3 earnings. EPS was reported at -1.96, versus the expected 0, missing expectations. The chart below visualizes how OGEN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
